Key Charpentier/Doudna CRISPR patent upheld by Japanese Patent Office

Patent JP6692856 upheld for second time in response to invalidation challenge.

SolasCure demonstrates proof-of-concept in Phase lla safety trial of Aurase Wound Gel

Cambridge, UK: SolasCure, a biotechnology company developing a hydrogel containing tarumase (provisional INN), a recombinant enzyme derived from maggots, and which aims to accelerate wound debridement and contribute to wound bed preparation & healing, announces the results of its proof-of-concept, first-in-human, Phase IIa safety study.

DeepMirror launches early access programme for its intuitive molecular drug design software

Cambridge, UK - DeepMirror, a University of Cambridge spin-out company developing intuitive design software for the discovery of novel therapeutic drugs, announces the launch of its Early Access Programme after a successful closed beta programme during which chemists were invited to test the software over several months. The software allows users to tap into AI-driven insights to improve and…

Gyros Protein Technologies and Biotage partner to advance peptide purification efficiency with new automated solution

Optibrium’s Quantum Mechanics and Machine Learning Methods Predict Routes of Drug Metabolism

Peer-reviewed study published in Xenobiotica describes an innovative new method that predicts the routes and products of Phase I and II metabolism with high sensitivity and greater precision than other approaches

Camena Bioscience appoints Dr Nicola Thompson as Chair of the Board

Cambridge, UK: Camena Bioscience, a synthetic biology company providing genes to the pharmaceutical and biotechnology industries, announces it has appointed Dr Nicola Thompson as Chair of its Board of Directors. Following its $10 million Series A financing earlier in the year1, the appointment forms part of the Company’s growth plans to expand commercialisation of its pioneering DNA synthesis…

PlaqueTec recruits first ten patients in BIOPATTERN trial

Cambridge, UK: PlaqueTec, a company identifying endotype-specific biomarkers to advance precision medicine for coronary artery disease (CAD), announces that it has received the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) approval to continue its BIOPATTERN trial following recruitment of the first ten patients with CAD.

Exonate announces successful completion of Phase Ib/IIa trial in diabetic macular oedema

Cambridgeshire and Nottingham, UK, 28 November 2023: Exonate Ltd., an mRNA therapy company focused on treatments for diabetic complications, announces its lead ophthalmology asset, EXN407, has achieved its prespecified endpoints in a phase Ib/IIa study.

OBN (UK) Ltd shines a light on outstanding companies within the life sciences industry, at the 2023 OBN Awards, 22 November 2023, London

Abingdon, UK – OBN (UK) Ltd., the not-for-profit membership organisation that catalyses growth for the life sciences industry, is delighted to announce the winners of their 2023 OBN Awards, presented at the Royal Lancaster, London, on Wednesday 22 November.

NanoSyrinx appoints Anthony Johnson as Non-Executive Director

Appointment of Big Pharma executive strengthens leadership team to drive ambitious growth strategy

Lario Therapeutics receives “Company Making a Difference Award” from CDLK5 Forum, recognising its unique approach to precision medicine for genetic epilepsies

Enhanc3D Genomics expands leadership team with the appointment of Hazel Jones as Chief Operating Officer

Cambridge, UK - Enhanc3D Genomics, a company developing disruptive technologies to unlock the 3D spatial genome for target and biomarker discovery, announces the appointment of Hazel Jones as Chief Operating Officer.

Antiverse and GlobalBio, Inc. extend collaboration to advance antibody cancer therapeutics

Cardiff, UK and Massachusetts, US - Antiverse Ltd (Antiverse), a biotechnology company developing a computational antibody drug discovery platform, and GlobalBio, Inc. (GlobalBio), an antibody engineering company developing methods to engineer improved and more developable therapeutic antibodies, announces they will be extending their collaboration to advance immune checkpoint inhibitors in…

Closed Loop Medicine appoints Konstantinos Vlassis as Chief Technology Officer

London, UK - Closed Loop Medicine Ltd., a leading TechBio company developing combination prescription drug plus software therapy products that enable personalized dose optimization, announces that it has appointed Konstantinos Vlassis as Chief Technology Officer (CTO).

Owlstone Medical recruits first patient in phase 2 clinical trial for the early detection of lung cancer through breath biopsy

Cambridge, UK - Owlstone Medical, the global leader in Breath Biopsy® for applications in early disease detection and precision medicine, today announced recruitment of the first patient into its EVOLUTION Phase 2 clinical trial following successful achievement of key safety and proof of concept milestones in Phase 1.

Bio-Rad extends range of anti-idiotypic antibodies for use in preclinical and clinical drug development

Range of Highly Selective Anti-Idiotypic Antibodies Now Includes Six Antibodies Specific to Dupilumab and its Biosimilars for Bioanalysis and Drug Monitoring.

FUJIFILM Diosynth Biotechnologies President and CEO Lars Petersen appoints Maja Pedersen as Chief Quality Officer

Hillerød, Denmark – FUJIFILM Diosynth Biotechnologies President and CEO Lars Petersen announces a new strategic leadership appointment to support the company through its next growth phase.

Ubiquigent collaborates with Imperial College London on DUB probe discovery to facilitate preclinical and clinical target engagement studies

Dundee, UK: Ubiquigent Limited (Ubiquigent), a drug discovery and development company harnessing novel deubiquitinase (DUB) modulators as new therapeutics for areas of high unmet medical need,  announces it is supporting a PhD student in the Institute of Chemical Biology EPSRC Centre for Doctoral Training (CDT) in Chemical Biology, at Imperial College London.

Bio-Rad launches PTC Tempo 48/48 and PTC Tempo 384 Thermal Cyclers

HERCULES, Calif. — Bio-Rad Laboratories, Inc., a global leader in life science research and clinical diagnostic products, announces the launch of its PTC Tempo 48/48 and PTC Tempo 384 Thermal Cyclers, designed to support PCR applications in basic and translational research, process development, and quality control. 

Start Codon invites life sciences leaders, founders and investors to Innovation Showcase 2023

Cambridge, UK - Start Codon, a life science and healthcare venture-building fund, is pleased to invite life sciences leaders, entrepreneurs, and investors from across the life science and biotech industries to attend their Innovation Showcase 2023.

Astrea Bioseparations expands manufacturing and warehousing capacity to support growing demand for its chromatography solutions in North America

Cambridge, UK - Astrea Bioseparations, a leading provider of high-quality bioseparation and purification technologies that help to improve patient outcomes with safer and more effective production of therapeutics, announces the expansion of its manufacturing and warehousing capabilities in the US. The increased capacity reflects growing demand for the Company’s chromatography solutions in North…

Orano Med and Orbit Discovery enter Collaboration to discover novel targeted radioligand therapies for cancer

Texas, US and Oxford, UK - Orano Med SAS, “Orano Med”, a biotechnology company developing Lead-212 (212Pb) Targeted Alpha Therapy against cancer, and Orbit Discovery Ltd, “Orbit”, a leader in the discovery of therapeutic peptide hits, announce that they have entered into a collaboration to discover specific Peptide Receptor Radionuclide Therapies against cancer cells and advance the development…

Bio-Rad Launches First StarBright™ Red Dye and Extends Range of Antibody Markers Conjugated to StarBright Dyes to Enhance Multiplex Flow Cytometry and Research Capabilities

With 29 additional targets the range also includes dog, cow, and pig targets to support translational models in veterinary immunology research.

GADx’s rapid diagnostic test, BotrytisAlert, demonstrates utility across wine production system

Ubiquigent appoints Dr Rishi Shah as Head of Chemistry

Appointment brings extensive heterobifunctional and chemical biology expertise in house to drive forward Ubiquigent’s internal DUBTAC drug discovery and DUB-focused partnerships